Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stifel Nicolaus Starts CymaBay Therapeutic (CBAY) at Buy
September 17, 2014 6:40 AM EDTStifel Nicolaus initiated coverage on CymaBay Therapeutic (NASDAQ: CBAY) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.
Shares of CymaBay Therapeutic closed at $7.37 yesterday.
... More